StockData
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. (ZBIO) stock

ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$23.85−1.19 (-4.75%)

Close on Nov 20, 2026Market cap $1.55BP/E –Yield –

Zenas BioPharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Zenas BioPharma's free cash flow for the twelve months ending Sep 30, 2026 was -$242.83M. For fiscal 2025 it was -$172.35M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$172.35M–
FY2024Dec 31, 2024-$119.81M–
FY2023Dec 31, 2023-$30.55M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$57.99M–
Q2 FY2026Jun 30, 2026-$57.24M–
Q1 FY2026Mar 31, 2026-$75.20M–
Q4 FY2025Dec 31, 2025-$52.41M–
Q3 FY2025Sep 30, 2025-$41.13M–
Q2 FY2025Jun 30, 2025-$41.74M–
Q1 FY2025Mar 31, 2025-$37.07M–
Q4 FY2024Dec 31, 2024-$38.63M–
Q3 FY2024Sep 30, 2024-$31.06M–
Q2 FY2024Jun 30, 2024-$30.99M–
Q1 FY2024Mar 31, 2024-$19.12M–

More Zenas BioPharma figures

See a number that looks wrong?